Insulet Co. (NASDAQ:PODD) Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its stake in shares of Insulet Co. (NASDAQ:PODD) by 15.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 188,532 shares of the medical instruments supplier’s stock after purchasing an additional 24,892 shares during the quarter. Envestnet Asset Management Inc. owned about 0.27% of Insulet worth $49,220,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of the stock. Katamaran Capital LLP acquired a new stake in Insulet in the fourth quarter valued at $444,000. Aviva PLC increased its holdings in shares of Insulet by 164.5% in the 4th quarter. Aviva PLC now owns 42,276 shares of the medical instruments supplier’s stock valued at $11,037,000 after purchasing an additional 26,294 shares in the last quarter. Rhenman & Partners Asset Management AB lifted its stake in shares of Insulet by 42.5% in the fourth quarter. Rhenman & Partners Asset Management AB now owns 57,000 shares of the medical instruments supplier’s stock valued at $14,881,000 after purchasing an additional 17,000 shares during the period. Resona Asset Management Co. Ltd. purchased a new stake in Insulet during the fourth quarter worth about $6,469,000. Finally, Motley Fool Asset Management LLC grew its position in Insulet by 13.5% during the fourth quarter. Motley Fool Asset Management LLC now owns 1,556 shares of the medical instruments supplier’s stock worth $406,000 after buying an additional 185 shares during the period.

Insider Activity

In other news, Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction dated Tuesday, March 25th. The stock was sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares in the company, valued at approximately $888,525. This represents a 36.10 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Benjamin sold 12,394 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total value of $3,470,320.00. Following the completion of the sale, the executive vice president now owns 11,383 shares in the company, valued at approximately $3,187,240. This represents a 52.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.47% of the stock is currently owned by corporate insiders.

Insulet Price Performance

PODD stock opened at $251.47 on Friday. The firm has a 50-day moving average of $267.16 and a two-hundred day moving average of $260.28. The firm has a market capitalization of $17.66 billion, a PE ratio of 43.43, a P/E/G ratio of 3.62 and a beta of 1.30. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a one year low of $160.19 and a one year high of $289.46.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.00 by $0.15. Insulet had a net margin of 20.19% and a return on equity of 24.46%. The firm had revenue of $597.50 million during the quarter, compared to analyst estimates of $582.02 million. On average, analysts forecast that Insulet Co. will post 3.92 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on PODD shares. Royal Bank of Canada began coverage on Insulet in a research note on Thursday, March 6th. They set an “outperform” rating and a $340.00 price target for the company. Stifel Nicolaus lifted their target price on shares of Insulet from $245.00 to $293.00 and gave the stock a “hold” rating in a research report on Friday, February 21st. Canaccord Genuity Group increased their price target on shares of Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research report on Friday, February 21st. JPMorgan Chase & Co. lifted their price objective on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Finally, Citigroup increased their target price on Insulet from $310.00 to $355.00 and gave the company a “buy” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Insulet has an average rating of “Moderate Buy” and an average target price of $292.06.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.